ReviewNeuroscience applied2024
Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects.
Review in Neuroscience applied, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin.Molecular psychiatry · 2026Trial
- Ten practical suggestions for setting up a psychedelic study.Journal of psychopharmacology (Oxford, England) · 2026Article
- Psilocybin shapes the slow, global propagation of brain activity over the cortical layout of 5HT2a receptors.Communications biology · 2026Article
- Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities.Addiction (Abingdon, England) · 2025Article
- A review of psychedelics trials completed in depression, informed by European regulatory perspectives.Neuroscience applied · 2025Review
- Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design.Journal of eating disorders · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychedelic drugs including psilocybin and LSD are undergoing clinical trials for a range of psychiatric and neurological conditions, and have particularly shown substantial promise in phase 2 studies of depression. In this article we outline key knowledge gaps that may be imperative for a successful implementation of psychedelic drugs as medicines as identified by members of the European College of Neuropsychopharmacology at the New Frontiers Meeting in Nice (2023). Key themes include pharmacokinetic and pharmacodynamic characterisation, comparisons between psychedelics, the relation between the duration of subjective effects and therapeutic outcomes, polypharmacology, and the impact of psychological support. We conclude with a perspective from the European Medicines Agency and Heath Technology Assessors on the most pressing requirements for medical implementation in Europe.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.